Tuesday, 30 July
MilliporeSigma Industry-Sponsored Symposium

 

Tapping the Potential of Gene Editing Technology to Improve Cell-Based Assays for Drug Disposition and Transporter-Mediated Drug-Drug Interactions

Speaker: David Thompson Ph.D., Sr R&D Manager, In Vitro Safety Systems, MilliporeSigma

Time: 17:30 - 18:30

Educational Needs Statement: This symposium is intended to present an overview of recent advances in gene editing technologies, particularly CRISPR-based reagents, and provide practical examples of how these tools are being utilized in the ADME/Tox field.

Learning Objectives:

  • Review recent advances in gene editing technology to modify the activity of genes of interest

  • Learn about various applications of this technology to the ADME/Tox field

  • Hear specific examples of drug transporter knockout/knockin cell lines

Who Should Attend?

  • Academic researchers

  • Pharma researchers

  • ADME scientists

  • DMPK scientists

  • Drug discovery scientists

Abstract:

Advances in gene editing technologies have generated a great amount of interest within the scientific community over the past few years. In addition to the ability to make precise double stranded DNA cuts virtually anywhere in the human genome, new variations of these tools show promise in the ability to activate or repress the expression of individual genes. Besides the obvious interest in clinical applications for these tools, there are practical uses of these tools for modifying and improving in vitro cell-based assays in areas such as preclinical ADME/Tox. This talk will highlight these recent advances in gene editing technology and provide several examples of how this technology has been applied to ADME/Tox assays, including intestinal, hepatic and renal proximal tubule cell lines.